Answers are grounded in this paper and cite their sources.
Hypertension is a risk factor for experiencing left ventricular ejection fraction (LVEF) declines during receipt of potentially cardiotoxic breast cancer (BC) treatment. We sought to determine whether the hypertension stage is associated with LVEF decline during BC treatment.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: